Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Kantarjian, HM; Roboz, GJ; Rizzieri, DA; Stock, W; O'Connell, CL; Griffiths, EA; Yee, K; Tibes, R; Garcia-Manero, G; Ravandi, F; Walsh, K; Feldman, E; Ritchie, E; Rao, A; Decastro, C; Schimmer, AD; Mesa, RA; Syed, I; Choy, G; Oganesian, A; Taverna, P; Azab, M; Chung, W; Issa, J-P

Published Date

  • November 16, 2012

Published In

Volume / Issue

  • 120 / 21

Published By


  • 2

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • Atlanta, GA

Conference Start Date

  • December 8, 2012

Conference End Date

  • December 11, 2012